Serum autoantibodies in patients with primary sclerosing cholangitis

Journal of Hepatology

Volumn 32, Issue 2, 2000, Pages 182-187

  Angulo, Paul ^a   Peter, James B ^b   Gershwin, M Eric ^c   DeSotel, Carolee K ^a   Shoenfeld, Yehuda ^d   Ahmed, Alaa E E ^b   Lindor, Keith D ^a,e  

^a MAYO CLINIC   (United States)

^b Specialty Laboratories   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e Div Gastroenterol Hepatol M   (United States)

Author keywords

Autoantibodies; Inflammatory bowel diseases; Mayo risk score; Primary sclerosing cholangitis

Indexed keywords

ANTIBODY; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOID FACTOR; THYROID PEROXIDASE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CROHN DISEASE; DISEASE MARKER; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0033953626     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80061-6     Document Type: Article

References (41)

1. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology. 30:1999;325-332.
2. Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 23:1996;1369-1376.
3. Senaldi G, Donaldson PT, Magrin S, Farrant JM, Alexander GJM, Vergani D, et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology. 97:1989;1430-1434.
4. Bodenheimer HC, LaRusso NF, Thayer WR Jr., Charland C, Staples PJ, Ludwig J. Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology. 3:1983;150-154.
5. Minuk GY, Angus M, Brickman CM, Lawley TJ, Frank MM, Hoofnagle JH, et al. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology. 88:1985;166-170.
6. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 21:1980;870-877.
7. Boberg KM, Schrumpf E, Fausa O, Elgjo K, Kolmannskog F, Haaland T, et al. Hepatobiliary disease in ulcerative colitis. An analysis of 18 patients with hepatobiliary lesions classified as small-duct primary sclerosing cholangitis. Scand J Gastroenterol. 29:1994;744-752.
8. Zauli D, Schrumpf E, Crespi C, Cassani F, Fausa O, Asdland E. An antibody profile in primary sclerosing cholangitis. J Hepatol. 5:1987;14-18.
9. Kirby DF, Blei AT, Rosen ST, Vogelzang RL, Neiman HL. Primary sclerosing cholangitis in the presence of a lupus anticoagulant. Am J Med. 81:1986;1077-1080.
10. Wong SS, Lawton JWM. Case report. Anti-proteinase 3 antibody activity in a patient with primary sclerosing cholangitis: clinical remission following ursodeoxycholic acid therapy. J Gastroenterol Hepatol. 11:1996;1161-1163.
11. Gur H, Shen G, Sutjita M, Terrbery J, Alosachie I, Barka N, et al. Autoantibody profile of primary sclerosing cholangitis. Pathobiology. 63:1995;76-82.
12. Kim WR, Lindor KD, Poterucha JJ, Benson JT, Therneau TM, Dickson ER. The Mayo risk score increases rapidly in the terminal phase of primary sclerosing cholangitis. [abstract] Gastroenterology. 114:1998;A1274.
13. Ludwig J, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis. Peters RL, Craig JR. Liver Pathology - Contemporary Issues in Surgical Pathology. 1986;193-214 Churchill Livingstone, New York.
14. Hollingworth PN, Dawkins RL, Peter JB. Precise quantification of antinuclear antibodies on Hep-2 cells without the need for serial dilution. Clin Diag Lab Immunol. 4:1996;374-377.
15. Kalunian KC, Peter JB, Middlekauff HR, Sayre J, Ando DG, Mangotich M, et al. Clinical significance of a single test for anticardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med. 85:1988;602-608.
16. Tuomi T. Which antigens to use in the detection of rheumatoid factors? Comparison of patients with rheumatoid arthritis and subjects with 'false positive' rheumatoid factor reactions. Clin Exp Immunol. 77:1989;349-355.
17. Roitt IM, Doniach D. Immunofluorescence tests for the detection of antibodies. WHO Booklet of Immunological Techniques. 1972;1-12 World Health Organization, Geneva.
18. 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med. 93:1992;181-186.
19. Hailstrom O. Comparison of IgA-class reticulin and endomysium antibodies in coeliac disease and dermatitis herpetiformis. Gut. 30:1989;1225-1232.
20. Wang XH, Miyazaki Y, Shinomura Y, Moriyama Y, Nakamoto RK, Matsuzawa Y, et al. Characterization of human autoantibodies reactive to gastric parietal cells. Biochem Biophys Res Commun. 190:1993;207-214.
21. Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM, et al. A novel class of antigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentric glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med. 181:1995;585-597.
22. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein (BPI) is an important antigen for antineutrophil cytoplasmic antoantibodies (ANCA) in vasculitis. Clin Exp Immunol. 99:1995;49-56.
23. Gross WL, Csernok E, Szymkowiak CH. Antineutrophil cytoplasmic autoantibodies with specificity for proteinase 3. Peter JB, Shoenfeld Y. Autoantibodies. 1996;61-67 Elsevier Science B.V. Amsterdam; The Netherlands.
24. Blaser MJ, Perez-Perez GI, Lindenbaum J, Schneidman D, Van Deventer G, Marin-Sorensen M, et al. Association of infection due to Helicobacter pylori with specific upper gastrointestinal pathology. Rev Infect Dis. 13:(suppl 8):1991;S704-S708.
25. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 87:1990;4120-4124.
26. Van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es IA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. i:1985;425.
27. Gross WL, Csernok E, Schmitt WH. Antineutrophil cytoplamic autoantibodies: immunobiological aspects. Klin Wochenschr. 69:1991;558-566.
28. Mulder AH, Broekroelofs J, Horst G, Limburg PC, Nelis GF, Kallenberg CG. Antineutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol. 95:1994;490-497.
29. Kobayashi S, Nakanuma Y, Matsui O. Intrahepatic peribiliary vascular plexus in various hepatobiliary diseases: a histological survey. Hum Pathol. 25:1994;940-946.
30. Washington K, Clavien PA, Killenberg P. Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Hum Pathol. 28:1997;791-795.
31. Duerr RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 100:1991;1385-1391.
32. Klein R, Eisenburg J, Weber P, Seibold F, Berg PA. Significance and specificity of antibodies to neutrophils detected by western blot for the serological diagnosis of primary sclerosing cholangitis. Hepatology. 14:1991;1147-1152.
33. Lo SK, Fleming KA, Chapman RW. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase method. Gut. 33:1992;1370-1375.
34. Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauebruch T, et al. Atypical antineutrophil cytoplamic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology. 28:1998;332-340.
35. Zhao MH, Lockwood CM. Antineutrophil cytoplasm autoantibodies with specificity other than PR3 and MPO (X-ANCA). Peter JB, Shoenfeld Y. Autoantibodies. 1996;68-73 Elsevier Science B.V. Amsterdam, The Netherlands.
36. Stoffel MP, Csernok E, Herzeberg C, Johnson T, Carroll SF, Gross WL. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol. 104:1996;54-59.
37. Rozendaal C, Vanmillegendewit AWM, Haagsma EB, Horst G, Schwarze C, Peter HH, et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med. 105:1998;393-399.
38. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA. 87:1990;4115-4119.
39. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology. 13:1991;766-772.
40. Litchman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest. 90:1992;1313-1322.
41. Falk RJ, Sartor RB, Jones DA, Jeffries BD, Jennette JC. Antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis [abstract]. Clin Res. 38:1990;387A.